4.2 Article

Development of a high risk pancreatic screening clinic using 3.0 T MRI

期刊

FAMILIAL CANCER
卷 17, 期 1, 页码 101-111

出版社

SPRINGER
DOI: 10.1007/s10689-017-0057-z

关键词

Familial pancreatic cancer; High risk; Pancreas cancer screening

资金

  1. We Care Fund for Medical Innovation and Research
  2. Ronald Burklund Eich Pancreatic Research Fund
  3. Lockton Funds for Pancreatic Cancer Research from Department of Surgery at the Medical College of Wisconsin
  4. American Cancer Society [86-004-26]
  5. Department of Veterans Affairs

向作者/读者索取更多资源

Selective screening for pancreatic cancer (PC) has been proposed. We describe the establishment of a comprehensive multidisciplinary screening program using 3.0 T MRI. Criteria for screening included the presence of PC in: >= 2 first degree relatives (FDR), 1 FDR and 1 s degree relative (SDR), >= 3 any degree relatives (ADR), or any known hereditary cancer syndrome with increased PC risk. Imaging with 3.0 T MRI was performed routinely and endoscopic ultrasound was used selectively. Screening was completed in 75 patients (pts). Hereditary cancer syndromes were present in 42 (56%) of the 75 pts: BRCA2 (18), ATM (8), BRCA1 (6), CDKN2A (4), PALB2 (3), Lynch (2), and Peutz-Jeghers (1). A family history of PC was present in >= 2 FDR in 12 (16%) pts, 1 FDR and 1 SDR in 5 (7) pts, and >= 3 ADR in 16 (21%) pts. Of the 65 pts who received screening MRI, 28 (43%) pts had pancreatic cystic lesions identified, including 1 (1%) patient in whom a cholangiocarcinoma was diagnosed as well. No patient underwent surgical resection. Using a 3.0 T MRI to screen patients at high risk for developing PC identified radiographic abnormalities in 43% of patients, which were stable on subsequent surveillance. Specific guidelines for the frequency of surveillance and indications for surgery remain areas of active investigation as the global experience with high risk screening continues to mature.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据